Development and <i>in vitro/in vivo</i> evaluation of a novel benznidazole liquid dosage form using a quality‐by‐design approach

Abstract

Quality by design was a suitable approach to formulate a co-solvent system of benznidazole. The in vivo studies confirmed the suitability of the optimised such solutions to diminish both parasitaemia and mortality. Thus, this novel alternative should be taken into account for further clinical evaluation in all age ranges.